{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:42:32Z","timestamp":1791247352650,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1124\/jpet.103.049858","type":"journal-article","created":{"date-parts":[[2003,6,18]],"date-time":"2003-06-18T19:15:01Z","timestamp":1055963701000},"page":"124-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":197,"title":["Multidrug Resistance Protein MRP2 Contributes to Blood-Brain Barrier Function and Restricts Antiepileptic Drug Activity"],"prefix":"10.1016","volume":"306","author":[{"given":"Heidrun","family":"Potschka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Fedrowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.049858_bib1","doi-asserted-by":"crossref","unstructured":"Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, and Bradford HF (1998) Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2 S,2\u2032R,3\u2032R)-2-(2\u2032,3\u2032-dicarboxycyclopropyl)glycine (DCG-IV). Brain Res 805: 138\u2013143.","DOI":"10.1016\/S0006-8993(98)00698-2"},{"key":"10.1124\/jpet.103.049858_bib2","doi-asserted-by":"crossref","unstructured":"Ayrton A and Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31: 469\u2013497.","DOI":"10.1080\/00498250110060969"},{"key":"10.1124\/jpet.103.049858_bib3","doi-asserted-by":"crossref","unstructured":"Benveniste H and Hansen A (1991) Microdialysis in the Neurosciences (Robinson TE and Justice JB eds) pp 81\u2013102, Elsevier, Amsterdam.","DOI":"10.1016\/B978-0-444-81194-3.50009-5"},{"key":"10.1124\/jpet.103.049858_bib4","doi-asserted-by":"crossref","unstructured":"Borst P, Evers R, Kool M, and Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461: 347\u2013357.","DOI":"10.1016\/S0005-2736(99)00167-4"},{"key":"10.1124\/jpet.103.049858_bib5","doi-asserted-by":"crossref","unstructured":"Cherrington NJ, Hartley DP, Li N, Johnson DR, and Klaassen CD (2002) Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2 and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300: 97\u2013104.","DOI":"10.1124\/jpet.300.1.97"},{"key":"10.1124\/jpet.103.049858_bib6","doi-asserted-by":"crossref","unstructured":"Croucher MJ and Bradford HF (1991) The influence of strychnine-insensitive glycine receptor agonists and antagonists on generalized seizure thresholds. Brain Res 543: 91\u201396.","DOI":"10.1016\/0006-8993(91)91051-2"},{"key":"10.1124\/jpet.103.049858_bib7","doi-asserted-by":"crossref","unstructured":"Decleves X, Regina A, Laplanche JL, Roux F, Boval B, Launay JM, and Scherrmann JM (2000) Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J Neurosci Res 60: 594\u2013602.","DOI":"10.1002\/(SICI)1097-4547(20000601)60:5<594::AID-JNR4>3.0.CO;2-6"},{"key":"10.1124\/jpet.103.049858_bib8","doi-asserted-by":"crossref","unstructured":"Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, and Janigro D (2001) Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42: 1501\u20131506.","DOI":"10.1046\/j.1528-1157.2001.12301.x"},{"key":"10.1124\/jpet.103.049858_bib9","doi-asserted-by":"crossref","unstructured":"Frey H-H and L\u00f6scher W (1978) Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 17: 637\u2013642.","DOI":"10.1016\/0028-3908(78)90160-0"},{"key":"10.1124\/jpet.103.049858_bib10","doi-asserted-by":"crossref","unstructured":"Fricker G, Nobmann S, and Miller DS (2002) Permeability of porcine blood brain barrier to somatostatin analogues. Br J Pharmacol 135: 1308\u20131314.","DOI":"10.1038\/sj.bjp.0704557"},{"key":"10.1124\/jpet.103.049858_bib11","doi-asserted-by":"crossref","unstructured":"Fromm MF (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38: 69\u201374.","DOI":"10.5414\/CPP38069"},{"key":"10.1124\/jpet.103.049858_bib12","doi-asserted-by":"crossref","unstructured":"Gerk PM and Vore M (2002) Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 302: 407\u2013415.","DOI":"10.1124\/jpet.102.035014"},{"key":"10.1124\/jpet.103.049858_bib13","doi-asserted-by":"crossref","unstructured":"Gernert M and L\u00f6scher W (2001) Lack of robust anticonvulsant effects of muscimol microinfusions in the anterior substantia nigra of kindled rats. Eur J Pharmacol 432: 35\u201341.","DOI":"10.1016\/S0014-2999(01)01458-3"},{"key":"10.1124\/jpet.103.049858_bib14","doi-asserted-by":"crossref","unstructured":"Jansen PL, Peters WH, and Lamers WH (1985) Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 5: 573\u2013579.","DOI":"10.1002\/hep.1840050408"},{"key":"10.1124\/jpet.103.049858_bib15","doi-asserted-by":"crossref","unstructured":"K\u00f6nig J, Nies AT, Cui Y, Leier I, and Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity and MRP2-mediated drug resistance. Biochim Biophys Acta 1461: 377\u2013394.","DOI":"10.1016\/S0005-2736(99)00169-8"},{"key":"10.1124\/jpet.103.049858_bib16","doi-asserted-by":"crossref","unstructured":"Lee G, Dallas S, Hong M, and Bendayan R (2001) Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 53: 569\u2013596.","DOI":"10.1016\/S0031-6997(24)01513-8"},{"key":"10.1124\/jpet.103.049858_bib17","doi-asserted-by":"crossref","unstructured":"Leslie EM, Deeley RG, and Cole SP (2001) Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167: 3\u201323.","DOI":"10.1016\/S0300-483X(01)00454-1"},{"key":"10.1124\/jpet.103.049858_bib18","doi-asserted-by":"crossref","unstructured":"Litman T, Druley TE, Stein WD, and Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931\u2013959.","DOI":"10.1007\/PL00000912"},{"key":"10.1124\/jpet.103.049858_bib19","doi-asserted-by":"crossref","unstructured":"L\u00f6scher W, Fassbender CP, and Nolting B (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res 8: 79\u201394.","DOI":"10.1016\/0920-1211(91)90075-Q"},{"key":"10.1124\/jpet.103.049858_bib20","doi-asserted-by":"crossref","unstructured":"L\u00f6scher W and Potschka H (2002) Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 301: 7\u201314.","DOI":"10.1124\/jpet.301.1.7"},{"key":"10.1124\/jpet.103.049858_bib21","doi-asserted-by":"crossref","unstructured":"L\u00f6scher W, Reissm\u00fcller E, and Ebert U (2000) Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats. Epilepsy Res 40: 63\u201377.","DOI":"10.1016\/S0920-1211(00)00108-X"},{"key":"10.1124\/jpet.103.049858_bib22","doi-asserted-by":"crossref","unstructured":"Meier PJ and Stieger B (2002) Bile salt transporters. Annu Rev Physiol 64: 635\u2013661.","DOI":"10.1146\/annurev.physiol.64.082201.100300"},{"key":"10.1124\/jpet.103.049858_bib23","doi-asserted-by":"crossref","unstructured":"Miller DS, Graeff C, Droulle L, Fricker S, and Fricker G (2002) Xenobiotic efflux pumps in isolated fish brain capillaries. Am J Physiol Regul Integr Comp Physiol 282: R191\u2013R198.","DOI":"10.1152\/ajpregu.00305.2001"},{"key":"10.1124\/jpet.103.049858_bib24","doi-asserted-by":"crossref","unstructured":"Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drewe J, and Fricker G (2000) Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 58: 1357\u20131367.","DOI":"10.1124\/mol.58.6.1357"},{"key":"10.1124\/jpet.103.049858_bib25","doi-asserted-by":"crossref","unstructured":"Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, and Oude Elferink RP (1996) Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (Wash DC) 271: 1126\u20131128.","DOI":"10.1126\/science.271.5252.1126"},{"key":"10.1124\/jpet.103.049858_bib26","doi-asserted-by":"crossref","unstructured":"Potschka H, Fedrowitz M, and L\u00f6scher W (2001) P-Glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12: 3557\u20133560.","DOI":"10.1097\/00001756-200111160-00037"},{"key":"10.1124\/jpet.103.049858_bib27","doi-asserted-by":"crossref","unstructured":"Potschka H, Fedrowitz M, and L\u00f6scher W (2002) P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 327: 173\u2013176.","DOI":"10.1016\/S0304-3940(02)00423-8"},{"key":"10.1124\/jpet.103.049858_bib28","doi-asserted-by":"crossref","unstructured":"Potschka H and L\u00f6scher W (2001a) Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport 12: 2387\u20132389.","DOI":"10.1097\/00001756-200108080-00020"},{"key":"10.1124\/jpet.103.049858_bib29","doi-asserted-by":"crossref","unstructured":"Potschka H and L\u00f6scher W (2001b) In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 42: 1231\u20131240.","DOI":"10.1046\/j.1528-1157.2001.01901.x"},{"key":"10.1124\/jpet.103.049858_bib30","doi-asserted-by":"crossref","unstructured":"Potschka H and L\u00f6scher W (2002) A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats. Neuroreport 13: 167\u2013171.","DOI":"10.1097\/00001756-200201210-00038"},{"key":"10.1124\/jpet.103.049858_bib31","doi-asserted-by":"crossref","unstructured":"Racine RJ (1972) Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroenceph Clin Neurophysiol 32: 281\u2013294.","DOI":"10.1016\/0013-4694(72)90177-0"},{"key":"10.1124\/jpet.103.049858_bib32","doi-asserted-by":"crossref","unstructured":"Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud P-O, and Roux F (1998) Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71: 705\u2013715.","DOI":"10.1046\/j.1471-4159.1998.71020705.x"},{"key":"10.1124\/jpet.103.049858_bib33","doi-asserted-by":"crossref","unstructured":"Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, Aliprandi M, Bagnati R, Fanelli R, D\u2019Incalci M, et al. (2002) Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 22: 5833\u20135839.","DOI":"10.1523\/JNEUROSCI.22-14-05833.2002"},{"key":"10.1124\/jpet.103.049858_bib34","doi-asserted-by":"crossref","unstructured":"Rogawski MA and Porter RJ (1990) Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42: 223\u2013286.","DOI":"10.1016\/S0031-6997(25)00046-8"},{"key":"10.1124\/jpet.103.049858_bib35","doi-asserted-by":"crossref","unstructured":"Sato M, Racine RJ, and McIntyre DC (1990) Kindling: basic mechanisms and clinical validity. Electroenceph Clin Neurophysiol 76: 459\u2013472.","DOI":"10.1016\/0013-4694(90)90099-6"},{"key":"10.1124\/jpet.103.049858_bib36","doi-asserted-by":"crossref","unstructured":"Scheffer GL and Scheper RJ (2002) Drug resistance molecules: lessons from oncology. Novartis Found Symp 243: 19\u201331.","DOI":"10.1002\/0470846356.ch3"},{"key":"10.1124\/jpet.103.049858_bib37","doi-asserted-by":"crossref","unstructured":"Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36: 179\u2013194.","DOI":"10.1016\/S0169-409X(98)00085-4"},{"key":"10.1124\/jpet.103.049858_bib38","doi-asserted-by":"crossref","unstructured":"Silverman JA (1999) Multidrug-resistance transporters. Pharm Biotechnol 12: 353\u2013386.","DOI":"10.1007\/0-306-46812-3_13"},{"key":"10.1124\/jpet.103.049858_bib39","doi-asserted-by":"crossref","unstructured":"Taylor EM (2002) The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 41: 81\u201392.","DOI":"10.2165\/00003088-200241020-00001"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524307797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524307797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.049858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:27:01Z","timestamp":1739975221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524307797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["S0022356524307797"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.049858","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2003,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidrug Resistance Protein MRP2 Contributes to Blood-Brain Barrier Function and Restricts Antiepileptic Drug Activity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.049858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2003 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}